Nuvation Bio Inc. (NUVB)
| Market Cap | 1.34B -45.3% |
| Revenue (ttm) | 201.73M +654.2% |
| Net Income | -135.93M |
| EPS | -0.39 |
| Shares Out | 353.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,848,900 |
| Open | 3.770 |
| Previous Close | 3.810 |
| Day's Range | 3.720 - 3.910 |
| 52-Week Range | 3.710 - 9.750 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 12.45 (+227.63%) |
| Earnings Date | Nov 4, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $12.45, which is an increase of 227.63% from the latest price.
News
Nuvation Bio Transcript: Jefferies Global Healthcare Conference
IBTROZI sales grew 18% QoQ despite fewer ROS1 alerts, while management highlighted durable responses and a potential revenue-stacking opportunity. Safusidenib data are expected in 2027, alongside DDC platform updates and selective BD.
Nuvation Bio’s safusidenib shows benefits in Phase 2 IDH1-mutant glioma study
Nuvation Bio (NUVB) announced new long-term follow-up data from the Phase 2 study of investigational safusidenib in patients with chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma. The d...
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma Patients achieved a median ta...
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hu...
Nuvation Bio price target lowered to $11 from $13 at JPMorgan
JPMorgan analyst Priyanka Grover lowered the firm’s price target on Nuvation Bio (NUVB) to $11 from $13 and keeps an Overweight rating on the shares.
Nuvation Bio price target lowered to $13 from $14 at B. Riley
B. Riley lowered the firm’s price target on Nuvation Bio (NUVB) to $13 from $14 and keeps a Buy rating on the shares. Nuvation Bio’s Q3 total revenue beat expectations…
Nuvation Bio Earnings Call Transcript: Q3 2026
Q3 revenue reached $45.0M, led by IBTROZI, which grew 18% QoQ despite a ROS1 market pullback. Safusidenib advanced with positive long-term J201 results, and available capital is expected to fund operations through profitability.
Nuvation Bio Quarterly report: Q3 2026
Nuvation Bio has published its Q3 2026 quarterly earnings report on November 4, 2026.
Nuvation Bio Earnings release: Q3 2026
Nuvation Bio released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Nuvation Bio reports Q3 EPS (12c), consensus (10c)
Reports Q3 revenue $44.95M, consensus $34.42M. As of September 30, Nuvation Bio (NUVB) had cash, cash equivalents, and marketable securities of $663.4M. “Just over one year after launch, IBTROZI was…
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and establ...
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase ...
Nuvation Bio to expand Phase 3 SIGMA study of safusidenib
Nuvation Bio (NUVB) announced that the pivotal Phase 3 SIGMA study of investigational safusidenib will expand to include study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain.
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a glob...
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announ...
Nuvation Bio initiated with a Buy at Citi
Citi initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $12 price target The firm views the company as an emerging oncology leader. The company’s Ibtrozi launch and…
Nuvation Bio Slides: Corporate presentation
Nuvation Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 18, 2026.
Nuvation Bio announces FDA approval of sNDA for Ibtrozi
Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positiv...
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approv...
Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies
Nuvation Bio (NUVB) announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating Ibtrozi – taletrectinib – in both TKI- naive and TKI-pretreated patients with advanced ROS1...
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner...
Nuvation Bio Transcript: Cantor Global Healthcare Conference
IBTROZI leads the ROS1 market with unmatched efficacy and safety, driving rapid adoption and strong revenue potential. Safusidenib shows promising results in glioma, targeting all subtypes with multiple trials underway. Robust cash reserves and a disciplined approach to business development support continued growth.
Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma, positioning it for significant market expansion. Educational efforts and improved testing are driving adoption, and the DDC platform promises future innovation.
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hu...